NCT03789110进行中（未招募）2 期
NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
- 试验地点
- 3
- 主要终点
- Overall Response Rate of Nivolumab in Combination With Ipilimumab
研究概览
简要总结
This research study is studying a drug combination of nivolumab and ipilimumab as a possible treatment for hypermutated HER2 negative breast cancer.
The drugs involved in this study are:
- Nivolumab (Opdivo ®)
- Ipilimumab (Yervoy ®)
详细描述
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors. Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent your body's immune system from stopping to fight this specific cancer.
The U.S. Food and Drug Administration (FDA) has not approved nivolumab for this specific disease but it has been approved for other uses including but not limited to non-small cell lung cancer, melanoma and renal cell carcinoma.
The U.S. Food and Drug Administration (FDA) has not approved ipilimumab for this specific disease but it has been approved for other uses such as melanoma and renal cell carcinoma.
The combination of nivolumab with ipilimumab may or may not increase anti-cancer activity by further boosting the immune system. At this time, the FDA has not approved nivolumab in combination with ipilimumab for this specific disease although these drugs have been approved for other uses such as melanoma and renal cell carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must have histologically or cytologically confirmed invasive breast cancer, with metastatic disease. Participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation.
- •Breast cancer must be HER2-negative by IHC or non-amplified as determined by the current ASCO-CAP criteria. If patient has more than one histological result, the most recent one will be usedfor inclusion. Participants may be ER/PR positive or negative.
- •Patients must harbor tumors with total mutational burden (TMB) of at least 9 mutations per megabase assessed by a cancer-gene panel containing more than 300 genes, and performed in a CLIA verified laboratory. Tests like Foundation One, Oncopanel (DFCI), or IMPACT (MSKCC) are acceptable for including patients on this trial.
- •Participants must have measurable disease by RECIST version 1.
- •Participants must agree to undergo a research biopsy, if tumor is safely accessible, at baseline and at day 29 cycle 1 (+14 scheduling window). Previously collected archival tissue will be obtained on all participants. Participants for whom newly-obtained samples cannot be provided (e.g. inaccessible or participant safety concern) may submit an archived specimen (block or if not possible, 20 unstained slides).
- •Prior chemotherapy: Participants may have received 0-3 prior chemotherapeutic regimens for metastatic breast cancer and must have been off treatment with chemotherapy for at least 14 days prior to study treatment initiation.
- •Patients with hormone receptor positive breast cancer must have progressed on at least one prior line of endocrine therapy in the metastatic setting or have disease recurrence while on adjuvant endocrine therapy.
- •Participants should also be adequately recovered from acute toxicities of prior treatment, with the exception of alopecia and peripheral sensory neuropathy.
- •Prior biologic therapy: Patients must have discontinued all biologic therapy at least 14 days prior to study treatment initiation.
- •Prior radiation therapy: Patients may have received prior radiation therapy in either the metastatic or early-stage setting. Radiation therapy must be completed 14 days prior to study treatment initiation.
- •In all cases, there must be no ongoing complications from prior radiotherapy.
- •The subject is ≥18 years old.
- •ECOG performance status ≤1(Karnofsky ≥70%, see Appendix A).
- •Participants must have normal organ and marrow function as defined below:
- •absolute neutrophil count ≥1,000/mcL
- •platelets ≥100,000/mcL
- •hemoglobin ≥ 8 g/dl
- •total bilirubin ≤1.5 × institutional upper limit of normal (ULN) (or ≤ 2.0 x ULN in patients with documented Gilbert's Syndrome)
- •AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN or (≤ 3 × institutional ULN for participants with documented liver metastases)
- •creatinine ≤1.5 × institutional ULN OR creatinine clearance ≥ 40 mL/min (using Cockcroft-Gault formula) for participants with creatinine levels above institutional ULN.
- •Female subjects of childbearing potential must have a negative pregnancy test (serum or urine) at screening.
- •Childbearing potential is defined as: participants who have not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause) and has not undergone surgical sterilization (removal of ovaries and/or uterus).
- •Female and male participants of childbearing potential must agree to use an adequate method of contraception. For women, contraception is required starting with the first dose of study medication through 150 days (5 months) after the last dose of study medication. For men who are sexuall active with women of childbearing potential, contraception is required starting with the first dose of study medication for a period of 7 months after the last dose of nivolumab. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, established and proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- •Participants on bisphosphonates may continue receiving bisphosphonate therapy during study treatment. Initiation of bisphosphonate or RANKL agent is allowed on study.
- •The participant is capable of understanding and complying with the protocol and has signed the informed consent document.
排除标准
- •Major surgery within 2 weeks before the first dose of study treatment.
- •Concurrent administration of other anti-cancer therapy within 14 days of starting protocol therapy and during the course of this study.
- •The participant has received another investigational agent within 14 days of the first dose of study drug.
- •Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody.
- •Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms. Participants with a history of treated central nervous system (CNS) metastases are eligible. Treated brain metastases are defined as those having no evidence of progression for ≥ 2 weeks after treatment, and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging or CT scan) completed during screening. Subject must be either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily (or equivalent) for at least 7 days prior to first study treatment. Treatment for brain metastases may include whole brain radiotherapy, radiosurgery, or a combination as deemed appropriate by the treating physician. Participants with CNS metastases treated by neurosurgical resection or brain biopsy performed within 28 days before study treatment initiation will be excluded.
- •The subject has uncontrolled, significant intercurrent or recent illness. Individuals with a history of different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the investigator to be at low risk for recurrence of that malignancy.
- •Participant has an active infection requiring IV antibiotics at initiation of study therapy.
- •Patient has a medical condition that requires chronic systemic steroid therapy or on any other form of immunosuppressive medication. For example, participants with autoimmune disease that requires systemic steroids or immunosuppression agents should be excluded. Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •Subjects with current pneumonitis, or requiring supplementary O2 therapy.
- •The participant is known to be positive for human immunodeficiency virus (HIV), HepBsAg, or HCV RNA. HIV-positive participants on combination antiretroviral therapy are ineligible
- •Participants with any other active malignancy requiring concurrent intervention.
- •Known hypersensitivity to any of the components of ipilimumab or nivolumab.
- •The participant has received a live vaccine within 28 days prior to the first dose of trial treatment and while participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. The use of the inactivated seasonal influenza vaccine (Fluzone®) is allowed.
- •The participant is pregnant or breastfeeding.
研究组 & 干预措施
Nivolumab+Ipilimumab
Experimental
- Ipilimumab is administered intravenously every 6 weeks
- Nivolumab is administered intravenously every 2 weeks
干预措施: Ipilimumab (Drug)
Nivolumab+Ipilimumab
Experimental
- Ipilimumab is administered intravenously every 6 weeks
- Nivolumab is administered intravenously every 2 weeks
干预措施: Nivolumab (Drug)
结局指标
主要结局
Overall Response Rate of Nivolumab in Combination With Ipilimumab
时间窗: 2 years
Overall Response Rate (ORR) is defined as the proportion of patients with complete or partial response evaluated by RECIST 1.1. Per RECIST 1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
次要结局
- Overall Response Rate of the Combination According to Immune-related Response Criteria(2 years)
- Clinical Benefit Rate(2 Years)
- Progression Free Survival(2 years)
- Overall Survival(Participants were followed long-term for survival every 12 weeks from the end of treatment until death or lost to follow-up. Median follow-up in this study cohort was 9.7 months.)
研究者
Sara Tolaney, MD
Primary Investigator
Dana-Farber Cancer Institute
研究点 (3)
Loading locations...
相似试验
终止
2 期
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaRelapsed Multiple MyelomaRefractory Multiple MyelomaNCT04119336Andrew Yee, MD2
进行中（未招募）
2 期
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersMalignant Rhabdoid TumorRhabdoid Tumor of the KidneyEpithelioid SarcomaChordoma (Poorly Differentiated or De-differentiated)Atypical Teratoid/Rhabdoid TumorOther INI1 Negative Tumors (With PI Approval)Other SMARCA4-deficient Malignant Tumors (With PI Approval)NCT04416568Dana-Farber Cancer Institute30
进行中（未招募）
1 期
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerNon Small Cell Lung CancerLung Cancer, Nonsmall CellNon Small Cell Lung Cancer MetastaticNCT03377023H. Lee Moffitt Cancer Center and Research Institute66
进行中（未招募）
2 期
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerAnal Canal Squamous Cell CarcinomaMetastatic Anal Canal CarcinomaStage IV Anal Cancer AJCC v8NCT02314169National Cancer Institute (NCI)143
已完成
2 期
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine LeiomyosarcomaMetastatic LeiomyosarcomaUnresectable LeiomyosarcomaUterine Corpus LeiomyosarcomaNCT02428192National Cancer Institute (NCI)20